Zeke Capital Advisors LLC reduced its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 24.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,281 shares of the pharmaceutical company’s stock after selling 720 shares during the quarter. Zeke Capital Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $342,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently made changes to their positions in VRTX. Nationwide Fund Advisors raised its stake in Vertex Pharmaceuticals by 48.6% in the third quarter. Nationwide Fund Advisors now owns 173,157 shares of the pharmaceutical company’s stock valued at $26,327,000 after purchasing an additional 56,646 shares in the last quarter. Raymond James Financial Services Advisors Inc. raised its stake in Vertex Pharmaceuticals by 338.3% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 28,356 shares of the pharmaceutical company’s stock valued at $4,311,000 after purchasing an additional 21,887 shares in the last quarter. New York State Common Retirement Fund raised its stake in Vertex Pharmaceuticals by 3.5% in the third quarter. New York State Common Retirement Fund now owns 822,531 shares of the pharmaceutical company’s stock valued at $125,058,000 after purchasing an additional 27,484 shares in the last quarter. Teacher Retirement System of Texas raised its stake in Vertex Pharmaceuticals by 27.4% in the third quarter. Teacher Retirement System of Texas now owns 3,391 shares of the pharmaceutical company’s stock valued at $516,000 after purchasing an additional 730 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. raised its stake in Vertex Pharmaceuticals by 19.5% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 7,625 shares of the pharmaceutical company’s stock valued at $1,159,000 after purchasing an additional 1,242 shares in the last quarter. 94.48% of the stock is currently owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

Several research analysts have commented on the stock. BidaskClub raised shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, March 13th. TheStreet raised shares of Vertex Pharmaceuticals from a “c+” rating to a “b-” rating in a research note on Friday, March 2nd. Maxim Group lifted their price target on shares of Vertex Pharmaceuticals from $195.00 to $200.00 and gave the stock a “buy” rating in a research note on Monday, March 5th. Argus set a $194.00 price target on shares of Vertex Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, February 23rd. They noted that the move was a valuation call. Finally, Zacks Investment Research downgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, February 20th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and twenty-five have given a buy rating to the stock. Vertex Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $183.96.

In related news, CFO Thomas Graney sold 777 shares of Vertex Pharmaceuticals stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $149.95, for a total value of $116,511.15. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Jeffrey M. Leiden sold 99,563 shares of Vertex Pharmaceuticals stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $156.99, for a total transaction of $15,630,395.37. Following the completion of the sale, the chief executive officer now owns 176,747 shares in the company, valued at approximately $27,747,511.53. The disclosure for this sale can be found here. In the last quarter, insiders sold 356,966 shares of company stock worth $57,081,624. 1.80% of the stock is currently owned by company insiders.

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) traded up $0.28 during midday trading on Tuesday, hitting $171.05. 104,037 shares of the company traded hands, compared to its average volume of 1,827,801. The company has a current ratio of 3.28, a quick ratio of 3.14 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 12 month low of $88.90 and a 12 month high of $178.25. The stock has a market capitalization of $44,598.67, a P/E ratio of 164.20, a price-to-earnings-growth ratio of 2.50 and a beta of 1.56.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.53 by $0.08. The business had revenue of $651.63 million for the quarter, compared to analysts’ expectations of $592.49 million. Vertex Pharmaceuticals had a net margin of 10.59% and a return on equity of 11.02%. The firm’s revenue for the quarter was up 42.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.35 earnings per share. equities analysts predict that Vertex Pharmaceuticals Incorporated will post 1.67 EPS for the current year.

Vertex Pharmaceuticals announced that its board has authorized a stock repurchase plan on Wednesday, January 31st that authorizes the company to repurchase $500.00 million in outstanding shares. This repurchase authorization authorizes the pharmaceutical company to buy shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its stock is undervalued.

TRADEMARK VIOLATION WARNING: “Vertex Pharmaceuticals Incorporated (VRTX) Position Trimmed by Zeke Capital Advisors LLC” was first published by Watch List News and is owned by of Watch List News. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/vertex-pharmaceuticals-incorporated-vrtx-position-trimmed-by-zeke-capital-advisors-llc/1949339.html.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.